Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ORGESTRA

Financiado

Cerrado

Organoid technologies for disease modeling, drug discovery and development for r...

Organoid technologies for disease modeling, drug discovery and development for rare diseases The vast majority of rare diseases are characterized by genetic origin, often severe in pathology and with limited or no treatment options. This also includes the paediatric disorders cystic fibrosis (CF) and cystinosis. Both dise... ver más

31/12/2027

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

UNIVERSITEIT UTRECHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 14 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-07-11

HORIZON-MSCA-2022-DN-01-01: MSCA Doctoral Networks 2022 ExpectedOutcome:Project results are expected to contribute to the following outcomes:

I+D

Cerrada hace 2 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

14 Participantes

548.74K€ | Lider

FC.ID

486.81K€ | Participante

ASTRAZENECA AB

N.D. | Participante

UNL

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

HCA Organoid HCA Organoid Pilot action to establish a multi tissue human... 5M€ Cerrado

HIT-CF Personalised Treatment For Cystic Fibrosis Patients With Ult... 7M€ Cerrado

DISEASEAVATARS Modeling Disease through Cell Reprogramming a Translational... 2M€ Cerrado

PLEC2022-009255 ORGANOIDES DE TUMOR PANCREÁTICO DERIVADOS DE PACIENTES: UNA... 403K€ Cerrado

REMODEL Research models in infection cancer and regeneration repla... 800K€ Cerrado

CNS2023-145726 Herramientas diagnósticas, pronósticas y terapéuticas 200K€ Cerrado

Duración del proyecto: 53 meses Fecha Inicio: 2023-07-11
Fecha Fin: 2027-12-31

Líder del proyecto

UNIVERSITEIT UTRECHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The vast majority of rare diseases are characterized by genetic origin, often severe in pathology and with limited or no treatment options. This also includes the paediatric disorders cystic fibrosis (CF) and cystinosis. Both diseases usually manifest in the first year of life. In recent year, great progress has been made in CF research allowing a swift transfer of novel drugs from bench to bedside. This is fueled by the application of advanced in vitro models, viz. organoids, in phenotyping patients and personalize treatment options. In ORGESTRA, we propose to use stem cell-derived organoids to train 13 Doctoral Candidates (DCs) in developing personalized disease models for the lung and kidney diseases, CF and cystinosis, with significant unmet clinical needs. Research will aim to identify pathogenetic mechanisms and druggable targets, drug mode of action for effective and innovative treatment strategies, classify the pathway to clinic and address ethical and regulatory issues to foster acceptance and implementation of the organoid models. Eventually, a living technologies toolset will be developed for a swift transfer from bench to bedside. ORGESTRA will provide an international, intersectoral and interdisciplinary training by creating a new expert framework of 14 partners from 7 countries, combining molecular biologists, engineers, pharmacologists, clinicians, epidemiologists and ethicists, giving each DC unique, joint-doctoral training and tailored experience in industry and/or patient organisations, complemented with a rich workshop programme. The ORGESTRA objectives contribute perfectly to the Horizon Europe goals of the societal challenge on improving the health and well-being of the EU citizens.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores